title: Iridium 192 high-dose-rate brachytherapy--a useful alternative therapy for localized prostate cancer?
abstract: We report on a novel protocol involving iridium 192 high-dose-rate brachytherapy and follow-up of up to 130 months in patients with prostatic carcinoma. Using regional anesthesia, five to seven hollow needles are placed within the prostate by perineal puncture under ultrasound guidance. A 9-Gy prostate dose is applied followed by 30 min of hyperthermia (since 1991). This treatment is repeated once after 7 days; 2 weeks later, 18 x 2-Gy external beam radiation (small-field prostate) is added as percutaneous dose saturation. Since 1984 we have treated 40 patients with this protocol. Local tumor control was achieved by means of prostatic biopsy at 18 months after therapy and determination of prostate-specific antigen (PSA) values in about 70% of the patients; after a mean follow-up period of more than 6 years (16-130 months), 80% of the patients show either no evidence of disease or stable disease. We therefore conclude that iridium 192 high-dose-rate brachytherapy is a useful alternative in the treatment of localized prostate cancer in patients who are not eligible for radical prostatectomy.
authors.affiliation: Urologische Klinik und Poliklink der TU München, Klinikum rechts der Isar, Munich, Germany.
authors.forename: R
authors.initials: R
authors.lastname: Paul
authors.forename: R
authors.initials: R
authors.lastname: Hofmann
authors.forename: J U
authors.initials: JU
authors.lastname: Schwarzer
authors.forename: R
authors.initials: R
authors.lastname: Stepan
authors.forename: H J
authors.initials: HJ
authors.lastname: Feldmann
authors.forename: P
authors.initials: P
authors.lastname: Kneschaurek
authors.forename: M
authors.initials: M
authors.lastname: Molls
authors.forename: R
authors.initials: R
authors.lastname: Hartung
mesh_terms: D000328:Adult; D000368:Aged; D001918:Brachytherapy / Q000009:adverse effects; D002277:Carcinoma / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D018572:Disease-Free Survival; D007172:Erectile Dysfunction / Q000209:etiology; D005500:Follow-Up Studies; D006801:Humans; D007496:Iridium Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D012307:Risk Factors; D015996:Survival Rate
chemical_list: D007496:Iridium Radioisotopes